Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1 plus Cisplatin vs Vinorelbine plus Cisplatin for Resected NSCLC
NCT02223611Phase 2Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur + gimeracil + oteracil in non-small cell lung cancer (NSCLC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Disease-Free Survival Rate at 2 years. Status: unknown.
02
Drugs
tegafur + gimeracil + oteracil
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02223611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223611.